Participation, retention and uptake in a multicentre pre-exposure prophylaxis cohort using online, smartphone-compatible data collection.
HIV
cohort study
pre-exposure prophylaxis
prevention programme
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
24
08
2021
received:
19
05
2021
accepted:
07
09
2021
pubmed:
5
10
2021
medline:
15
3
2022
entrez:
4
10
2021
Statut:
ppublish
Résumé
The aim of the study was to assess the feasibility of a national pre-exposure prophylaxis (PrEP) programme using smartphone-compatible data collection. This was a multicentre cohort study (NCT03893188) enrolling individuals interested in PrEP in Switzerland. All centres participate in the SwissPrEPared programme, which uses smartphone-compatible data collection. Feasibility was assessed after centres had enrolled at least one participant. Participants were HIV-negative individuals presenting for PrEP counselling. Outcomes were participation (number enrolled/number eligible), enrolment rates (number enrolled per month), retention at first follow-up (number with first follow-up/number enrolled), and uptake (proportion attending first visit as scheduled). Participant characteristics were compared between those retained after baseline assessment and those who dropped out. Between April 2019 and January 2020, 987 individuals were assessed for eligibility, of whom 969 were enrolled (participation: 98.2%). The median enrolment rate was 86 per month [interquartile range (IQR) 52-137]. Retention at first follow-up and uptake were both 80.7% (782/969 and 532/659, respectively). At enrolment, the median age was 40 (IQR 33-47) years, 95% were men who have sex with men, 47% had a university degree, and 75.5% were already taking PrEP. Most reported multiple casual partners (89.2%), previous sexually transmitted infections (74%) and sexualized drug use (73.1%). At baseline, 25.5% tested positive for either syphilis, gonorrhoea or chlamydia. Participants who dropped out were at lower risk of HIV infection than those retained after baseline assessment. In a national PrEP programme using smartphone-compatible data collection, participation, retention and uptake were high. Participants retained after baseline assessment were at considerable risk of HIV infection. Younger, less educated individuals were underrepresented in the SwissPrEPared cohort.
Identifiants
pubmed: 34605153
doi: 10.1111/hiv.13175
pmc: PMC9292805
doi:
Substances chimiques
Anti-HIV Agents
0
Banques de données
ClinicalTrials.gov
['NCT03893188']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
146-158Informations de copyright
© 2021 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
PLoS One. 2018 Dec 3;13(12):e0208107
pubmed: 30507962
J Adolesc. 2021 Feb;87:1-5
pubmed: 33429132
Lancet HIV. 2018 Nov;5(11):e629-e637
pubmed: 30343026
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
J Int AIDS Soc. 2020 Apr;23(4):e25472
pubmed: 32294338
J Virus Erad. 2018 Oct 01;4(4):215-224
pubmed: 30515300
HIV Med. 2017 Nov;18(10):772-776
pubmed: 28544123
J Acquir Immune Defic Syndr. 2018 Apr 1;77(4):358-364
pubmed: 29210834
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Sex Transm Infect. 2018 Sep;94(6):457-462
pubmed: 29487172
EClinicalMedicine. 2020 Dec 01;29-30:100650
pubmed: 33305198
AIDS. 2017 Jul 31;31(12):1709-1714
pubmed: 28700394
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
J Sex Res. 2014;51(4):390-409
pubmed: 24754360
Sex Transm Infect. 2019 Jun;95(4):285-291
pubmed: 30679393
Curr HIV Res. 2018;16(3):237-249
pubmed: 30062970
JAMA. 2019 Apr 9;321(14):1380-1390
pubmed: 30964528
PLoS One. 2013 Dec 18;8(12):e81997
pubmed: 24367497
AIDS Behav. 2018 Apr;22(4):1265-1272
pubmed: 28884248
Sex Transm Dis. 2020 Aug;47(8):516-524
pubmed: 32658175
J Int AIDS Soc. 2019 Oct;22(10):e25407
pubmed: 31663257
BMJ Open. 2019 Jun 27;9(6):e028768
pubmed: 31248931
HIV Med. 2020 Apr;21(4):228-239
pubmed: 31849182
Clin Infect Dis. 2018 Aug 16;67(5):676-686
pubmed: 29509889
AIDS Behav. 2016 Jul;20(7):1461-9
pubmed: 25835463
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):540-546
pubmed: 27851714
AIDS. 2016 Sep 10;30(14):2251-2
pubmed: 27314179
J Int AIDS Soc. 2019 Feb;22(2):e25250
pubmed: 30768762
AIDS Behav. 2019 Oct;23(10):2730-2740
pubmed: 30953305
J Int AIDS Soc. 2019 Aug;22 Suppl 6:e25351
pubmed: 31468693
J Acquir Immune Defic Syndr. 2019 Dec;82 Suppl 3:S176-S182
pubmed: 31764252
N Engl J Med. 2015 Dec 3;373(23):2237-46
pubmed: 26624850
Euro Surveill. 2017 Jun 22;22(25):
pubmed: 28662762
BMC Med Res Methodol. 2014 Mar 25;14:42
pubmed: 24669751
HIV Med. 2022 Feb;23(2):146-158
pubmed: 34605153
Euro Surveill. 2019 Oct;24(41):
pubmed: 31615599
AIDS Behav. 2019 Jul;23(7):1708-1720
pubmed: 30306439
EClinicalMedicine. 2020 Feb 04;19:100263
pubmed: 32055792
Lancet HIV. 2017 Nov;4(11):e482-e483
pubmed: 29066095
Drugs. 2019 Apr;79(6):609-619
pubmed: 30963509